IHL - INCANNEX - HOLDERS RESEARCH, page-371

@Tyrannomorus

and another treatment indication for IHL-675A emerging before our eyes ....SARS - CoV-2 / COVID19 MIS

what is SARS-CoV-2 MIS ?
MultiSystem Inflammatory Syndrome - resulting post infection SARS-CoV-2 / Covid19 ( both adult and child cohort presentations)
criteria for classification of the syndrome
general criteria: 2 or more of the following
neutrophilia, lymphopenia, thrombocytopenia, hypoalbuminemia, elevated C-reactive protein, antagonist inflammatory interleukins IL-6 $ IL-1 biomarkers at elevated levels, elevated procalcitonin.....
virologic laboratory criteria; 1 or more of the following SARS-Co -2 test results
PCR &/or RAT detection of SARS-CoV-2 /Covid19 RNA in a clinical specimen
or its antigen present or present within the the prior 4 to 8 weeks
epidemiologic criteria; 1 or more of the following exposures in the 6 weeks prior to te onset of symptoms
close contact with an individual with confirmed SARS-CoV-2 infection
close contact with an individual with illness clinically compatible with Covid19 disease who had close contact with an individual with test confirmed SARS-CoV-2 infection
travel to or residence in an area with sustained ongoing community transmission of SARS-CoV-2

termed 'Covid Shock' and presenting clinical indicators of MIS in both adult and child cohorts
lymphopenia
severe abdominal pain
elevated CRP and IL-6 &IL-1 inflammatory antagonists
Myocarditis/myocardial dysfunction

is it reasonable to expect approved anti inflammatory medications will find MIS an emerging global un met need .....yes imo

would such a inflammation related and debilitating condition be within the remit of IHL-675A as 'The Treatment' to address this additional emerging disease / unmet need/ ....absolutely imo

addressable global market....as yet unquantified due to the emerging nature of both size, classification and infancy disease development status
Pediatric MIS-C diagnosis and standard -of-care options are developing at an increasing ratio to the global dult cohort as the disease emerges....this may well change over time and with future emerging viral strains of the disease.
plenty on the web for those interested.

plenty to unfold in the IHL-675A development pathway yet......exciting times for Incannex @Tyrannomorus
as an investor I'm not selling a single share - hoovering them up at every opportunity

( amazed this company remains so far under the radar at this point in its development - wait till it pops with the investment community....)